Dr. Schaller has published approximately 26 books. He has published six books related to Babesia, Lyme disease and Bartonella. Dr. Schaller has also worked, at a great financial loss, as a full time self-funded researcher. One of his projects was to test the effectiveness of inherited patients who were already using over twenty-five different herbs from all over the world. These herbs are sold as a cure for various infections. During this research, he found that some patients required extremely low starting doses of the Zhang formulas, and patients and healers often confused an allergic reaction with a die-off of Babesia, Lyme or Bartonella. Meaning, the herb was too effective and as little as 1/8th was enough for a month.
However, over time, many needed far more than one Zhang capsule three times a day for true cure. (Some also required other augmenting treatments). This aggressive examination of inherited patients led to a conference in Naples, Florida between Dr. Schaller and Dr. Ching Zhang, in which they shared their herbal research and purity findings.
The result was that after 18 months, and many trips to China, a high quality pure and more powerful Artemisia and HH options are now available.
Please never use either unless you are under the care of a licensed physician or expert in herbal medicine. As mentioned above, these are NOT starting doses.
Dr. Zhang Press Release
Why We Produce Double Strength HH2 and Artemisia 2 Capsules
In our Lyme disease herbal protocols, we have been using HH Capsule for anti-Lyme spirochete and co-infections, especially bartonella and Artemisia Capsule (in which the active ingredient is artesunate) for anti-babesiosis and Ehrlichiosis. After more than ten years clinical usage, we found that for certain part of the patients the dose may not strong enough in eradicating these pathogens. Dr. James Schaller has done clinical observations and found that with higher dosage, the therapeutic efficacy improves. He suggested us to produce double strength version of these two products. Now the double strength HH2 Capsule and Artemisia 2 Capsule are available.
Original HH Capsule contains 90 mg new sodium houttuyfonate in each capsule and one day three capsules make the daily dose of 270 mg of new sodium houttuyfonate. The HH2 Capsule contains 180 mg of new sodium houttuyfonate, the daily three capsules makes the daily dose of 540 mg per day. This double dose HH 2 Capsule may have stronger anti-infection especially anti-bartonella effects. At the same time the possible Herxheimer’s reaction strength may also be stronger. For people already responding to the original HH Capsule well, you don’t need to switch to the HH 2 Capsule. Only those do not respond to HH Capsule well and need increased dose can move to the higher dosage and try the HH 2 Capsule.
Original Artemisia Capsule contains active ingredient artesunate and every capsule has 33.33 mg of artesunate. One-day take three capsules makes daily dose of 100 mg, which is recommended anti-malaria dose. When used for anti-malaria, one-week treatment course is enough. But we have seen that even three months long treatment course still can’t totally eradicate the babesia in some patients. Therefore we developed this new Artemisia 2 Capsule. Its active ingredient is Dihydroartemisinin (DHA), a derivertive of artemisinin. It is a front line anti-malaria agent and has been effectively used for millions of malaria cases. It is much stronger than artemisinin and also has less adverse reactions. The recomemnded anti-malaria dose is 60 mg per day and its efficacy equvalent to 100 mg of artesunate. Now the Artemisia 2 Capsule contains 40 mg of DHA in each capsule, one day three capsules makes the daily dose of 120 mg of DHA. Therefore it is the double strength of anti-malaria dosage. For those patients have not respond to the Artemisia Capsule three capsules per day protocol, this new Artemisia 2 Capsule may help to increase the respond rate. At beginning the Herxheimer’s reaction strength may also increase.
We produce these two new version of HH 2 and Artemisia 2 Capsule is to make more choice available for patients. The original version has been work well for majority of patients. For those have not been respond to the original form of these two herbal products, the new versions provided alternatives.
Rapid and Complete Control of Idiopathic Hypereosinophilia With Imatinib Mesylate
Abstract
In this case report, we describe what we believe is the first case of imatinib mesylate, or STI-571 (Novartis), use for treatment of idiopathic hypereosinophilia syndrome (HES). HES is often a fatal illness, damaging the heart, nervous system, lungs, liver, and kidneys. It is often treated with interferon-alpha. In this patient, we combined it with hydroxyurea, and we believe it saved his life. However, he experienced many common side effects, such as a profound intractable headache, severe fatigue, and concentration difficulties. After years on hydroxyurea and interferon-alpha, the severity of these side effects motivated us to try a trial of imatinib mesylate. Its use was followed by an abrupt remission of HES in a few weeks, with no significant side effects.
A Different One
James Schaller, MD Discovers Babesia as a Cancer Primer
Are Various Babesia Species a Missed Cause for Hypereosinophilia? A Follow-Up on the First Reported Case of Imatinib Mesylate for Idiopathic Hypereosinophilia
James L. Schaller, MD, MAR; Glenn A. Burkland, DMD; PJ Langhoff
Medscape General Medicine. 2007;9(1):38. Posted 02/27/2007
Background
When Drs. Schaller and Burkland were sent readers’ responses to their 2001 MedGenMed article “Rapid and Complete Control of Idiopathic Hypereosinophilia With Imatinib Mesylate”, they submitted the following reply as an update.
Abstract Introduction
In 2001, we reported the first case of imatinib mesylate (Gleevec) use for treatment of idiopathic hypereosinophilia syndrome (HES). These findings have been replicated in some patients with HES. After 1 year of taking imatinib, the patient stopped this medication, and during the last 5 years the patient has not experienced a relapse. He has, however, recently been diagnosed with babesiosis. This new diagnosis might relate to his HES.
Methods
After 6 years we decided to follow up on this patient’s treatment. We interviewed the patient, his son, his aunt, and 2 consulting physicians and also reviewed relevant laboratory results to determine whether his HES had returned and whether his residual morbidity had changed.
Results
The patient has had no HES relapse, and his eosinophil counts have remained low-normal. He was recently diagnosed with babesiosis and was prescribed atovaquone and azithromycin, with a significant decrease in morbidity. His eosinophil cationic protein levels have also fallen to low-normal since starting atovaquone and azithromycin.
Discussion
New Babesia species are emerging as human infections. Most do not have available antibody or polymerase chain reaction diagnostic testing at this time. Manual differential examinations have variable utility because of low numbers of infected red blood cells, suboptimal technique, and limited experience. Therefore, a diagnosis might need to be empirical at times, and should be based on signs and symptoms.
Conclusion
The patient has not relapsed in the 5 years that he has not been taking imatinib. Babesiosis should be added to the many possible causes of HES. It is unknown how often babesiosis causes HES as well as what percentage of HES patients have babesiosis.